Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Department of Orthopaedic Surgery, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi, Japan.
Biomed Res Int. 2019 Jan 16;2019:5046852. doi: 10.1155/2019/5046852. eCollection 2019.
Osteoporosis is a common age-related disorder leading to increased bone fragility and risk of fracture. Early diagnosis of osteoporosis is a vital step in providing early therapeutic intervention. Serum cystatin C is a marker of early renal dysfunction, a predictor of cardiovascular and inflammatory diseases, and an inhibitor of the differentiation of osteoclast precursor cells. The purpose of this study was to evaluate the relationship between serum cystatin C and osteoporosis.
We enrolled 46 subjects who attended a health checkup and underwent measurement of bone status by quantitative ultrasound and determination of the level of serum cystatin C. A comparative study was conducted between those with and without osteoporosis for all subjects collectively and in two subgroups aged <65 and ≥65 years.
Serum cystatin C levels were strongly correlated with age, creatinine, and bone status data, with significant negative correlations with stiffness, T-score, and percentage of young adult mean. Among patients with osteoporosis, serum cystatin C was significantly higher even after adjustment for age and sex, whereas no significant difference was noted in creatinine. For patients aged ≥ 65 years, serum cystatin C was significantly higher in subjects with osteoporosis, although there was no significant difference in age between normal subjects and those with osteoporosis.
To the best of our knowledge, this is the first study to demonstrate an association between serum cystatin C and osteoporosis. Serum cystatin C is significantly higher in osteoporosis and in particular may be a useful marker for osteoporosis among middle and elderly people aged ≥ 65 years. Measurement of serum cystatin C can be carried out easily and may contribute to early diagnosis and treatment of osteoporosis.
骨质疏松症是一种常见的与年龄相关的疾病，会导致骨骼脆弱度增加和骨折风险上升。早期诊断骨质疏松症对于提供早期治疗干预至关重要。血清胱抑素 C 是早期肾功能障碍的标志物，是心血管和炎症性疾病的预测指标，也是破骨细胞前体细胞分化的抑制剂。本研究旨在评估血清胱抑素 C 与骨质疏松症之间的关系。
我们纳入了 46 名参加健康检查并接受定量超声骨状态测量和血清胱抑素 C 水平测定的受试者。对所有受试者以及年龄<65 岁和≥65 岁的两个亚组进行了有无骨质疏松症的比较研究。
血清胱抑素 C 水平与年龄、肌酐和骨状态数据密切相关，与刚度、T 评分和年轻成年人平均值的百分比呈显著负相关。在骨质疏松症患者中，即使在调整了年龄和性别后，血清胱抑素 C 水平仍然显著升高，而肌酐则没有显著差异。对于年龄≥65 岁的患者，骨质疏松症患者的血清胱抑素 C 水平显著升高，尽管正常受试者和骨质疏松症患者之间的年龄无显著差异。
据我们所知，这是第一项表明血清胱抑素 C 与骨质疏松症之间存在关联的研究。在骨质疏松症中，血清胱抑素 C 显著升高，特别是在年龄≥65 岁的中老年人中，可能是骨质疏松症的有用标志物。血清胱抑素 C 的测量简单易行，可能有助于早期诊断和治疗骨质疏松症。
